IMBdx Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
57
- Stock Symbol
-
461030
- Share Price
-
$10.53
- (As of Tuesday Closing)
IMBdx General Information
Description
IMBdx Inc detects and analyzes the genomic profile of tumor DNA with a single draw of blood. It provides personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Its AlphaLiquid platform offers ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection (AlphaLiquid 100/HRR) to recurrence and minimal residual disease(MRD) monitoring (CancerDetect), and multi-cancer early detection (CancerFind). Its services are Clinical Service BioPharma, Research, and Healthcare Checkup.
Contact Information
Website
www.imbdx.comCorporate Office
- 131 Gasan Digital 1-ro, Geumcheon-gu
- 21st Floor, Building A, BYC High City Building
- Seoul, 08506
- South Korea
Corporate Office
- 131 Gasan Digital 1-ro, Geumcheon-gu
- 21st Floor, Building A, BYC High City Building
- Seoul, 08506
- South Korea
IMBdx Stock Performance
(As of Tuesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$10.53 | $10.80 | $6.09 - $29.98 | $148M | 14M | 1.4M | -$0.52 |
IMBdx Financials Summary
In Thousands, USD |
TTM 31-Mar-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
Revenue | 3,330 | 3,080 | 2,031 | 1,074 |
EBITDA | (5,977) | (6,149) | (5,905) | (7,047) |
Net Income | (7,494) | (7,967) | (8,077) | (8,546) |
Total Assets | 30,260 | 7,621 | 13,738 | 20,195 |
Total Debt | 190 | 249 | 193 | 168 |
IMBdx Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
IMBdx Comparisons
Industry
Financing
Details
IMBdx Competitors (5)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Foundation Medicine | Formerly VC-backed | Cambridge, MA | ||||
Guardant Health | Formerly VC-backed | Palo Alto, CA | ||||
Natera | Formerly VC-backed | Austin, TX | ||||
GRAIL | Formerly VC-backed | Menlo Park, CA | ||||
Freenome | Venture Capital-Backed | San Francisco, CA |
IMBdx Patents
IMBdx Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4282984-A1 | Method for construction of multi-feature prediction model for cancer diagnosis | Pending | 29-Mar-2022 | ||
EP-4287213-A1 | Method for predicting cancer recurrence using patient-specific panel | Pending | 29-Mar-2022 | ||
US-20240318253-A1 | Method of predicting cancer recurrence using patient-specific panel | Pending | 29-Mar-2022 | ||
US-20240312563-A1 | Method for preparation of multi-analytical prediction model for cancer diagnosis | Pending | 29-Mar-2022 | ||
US-20240296905-A1 | Method of identifying false positive variants in nucleic acid sequencing | Pending | 21-Mar-2022 | G16B20/20 |
IMBdx Signals
IMBdx Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
IMBdx FAQs
-
When was IMBdx founded?
IMBdx was founded in 2018.
-
Where is IMBdx headquartered?
IMBdx is headquartered in Seoul, South Korea.
-
What is the size of IMBdx?
IMBdx has 57 total employees.
-
What industry is IMBdx in?
IMBdx’s primary industry is Drug Discovery.
-
Is IMBdx a private or public company?
IMBdx is a Public company.
-
What is IMBdx’s stock symbol?
The ticker symbol for IMBdx is 461030.
-
What is the current stock price of IMBdx?
As of 05-Nov-2024 the stock price of IMBdx is $10.53.
-
What is the current market cap of IMBdx?
The current market capitalization of IMBdx is $148M.
-
What is IMBdx’s current revenue?
The trailing twelve month revenue for IMBdx is $3.33M.
-
Who are IMBdx’s competitors?
Foundation Medicine, Guardant Health, Natera, GRAIL, and Freenome are competitors of IMBdx.
-
What is IMBdx’s annual earnings per share (EPS)?
IMBdx’s EPS for 12 months was -$0.52.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »